Toronto, Ontario – February 6, 2025 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has signed an advisory agreement with Mr. Matthew Azrieli. Mr. Azrieli is a current shareholder of PharmAla Biotech.
“Having come to know Matthew well over the past number of months, I believe he will be able to significantly help PharmAla in a number of our developing markets” said Nick Kadysh, CEO, PharmAla Biotech. “Mr. Azrieli is not only well placed to assist PharmAla in highlighting our growing Clinical Trials business in the United States, but is also well placed to assist our work in a number of other growth markets.”
The advisory agreement with Mr. Azrieli includes up to 1 million Performance Share Units, which may be released to Mr. Azrieli upon execution of pre-set corporate goals spanning 3 major categories: media advisory, market development, and investment advisory.
Investor Webinar
PharmAla will host a Webinar on February 6, 2025, at 4:30 PM Eastern Time (ET). Nicholas Kadysh, CEO, and Will Avery, CFO, will discuss the Company’s financial results, as well as the Company’s plans for the coming year.
What: PharmAla Earnings/Financials Webinar
When: February 6, 4:30PM ET
Sign-up Link:
https://us06web.zoom.us/webinar/register/WN_YVwEWTKGTPKWQolPPelDtg
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO
press@pharmala.ca